MONOCLONAL-ANTIBODIES (MABS) THAT MODULATE THE RESPONSE OF NATURAL-KILLER (NK) CELLS AND LYMPHOKINE ACTIVATED KILLER (LAK) CELLS TO RECOMBINANT INTERLEUKIN-2

被引：0
|
作者：
VUJANOVIC, NL
CHAMBERS, WH
DELEO, AB
HERBERMAN, RB
HISERODT, JC
机构：
[1] PITTSBURGH CANC INST, PITTSBURGH, PA USA
[2] UNIV PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA 15213 USA
来源：
FASEB JOURNAL | 1988年 / 2卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A1652 / A1652
页数：1
相关论文
共 50 条
  • [21] LEU-11+ LYMPHOCYTES WITH NATURAL-KILLER (NK) ACTIVITY ARE PRECURSORS OF RECOMBINANT INTERLEUKIN-2 (RIL 2)-INDUCED ACTIVATED KILLER (AK) CELLS
    ITOH, K
    TILDEN, AB
    KUMAGAI, K
    BALCH, CM
    JOURNAL OF IMMUNOLOGY, 1985, 134 (02): : 802 - 807
  • [22] NATURAL-KILLER (NK) AND LYMPHOKINE-ACTIVATED KILLER (LAK) CELLS REQUIRE GRANZYME-B FOR THE RAPID INDUCTION OF APOPTOSIS IN TARGET-CELLS
    SHRESTA, S
    MACIVOR, D
    HEUSEL, J
    LEY, TJ
    BLOOD, 1994, 84 (10) : A109 - A109
  • [23] SPECIFIC ACTIVATION OF LYMPHOKINE ACTIVATED KILLER (LAK) CELLS BY MONOCLONAL-ANTIBODIES (MABS) SPECIFIC FOR THE NK1.1, LY-6, AND VEA ANTIGENS - NK CELLS CAN BE ACTIVATED ONLY BY ANTI-NK1.1
    KARLHOFER, FM
    YOKOYAMA, WM
    FASEB JOURNAL, 1991, 5 (05): : A1099 - A1099
  • [24] IMMUNOTHERAPY OF TUMORS WITH INTERLEUKIN-2 AND LYMPHOKINE ACTIVATED KILLER CELLS
    JOST, LM
    GMUR, J
    OELZ, O
    SAUTER, C
    STAHEL, RA
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1989, 119 (05) : 137 - 143
  • [25] TREATMENT WITH LYMPHOKINE-ACTIVATED KILLER CELLS AND INTERLEUKIN-2
    DEGOS, L
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1988, 30 (1-2): : 119 - 122
  • [26] EFFECTS OF SYSTEMIC RECOMBINANT INTERLEUKIN-2 ON NATURAL-KILLER AND LYMPHOKINE ACTIVATED KILLER ACTIVITY OF HUMAN-TUMOR INFILTRATING LYMPHOCYTES
    ANDERSON, TM
    IBAYASHI, Y
    TOKUDA, Y
    COLQUHOUN, SD
    HOLMES, EC
    GOLUB, SH
    CANCER RESEARCH, 1988, 48 (05) : 1180 - 1183
  • [27] EVALUATION OF NATURAL-KILLER AND LYMPHOKINE-ACTIVATED KILLER (LAK) CELL-ACTIVITY INVIVO IN PATIENTS TREATED WITH HIGH-DOSE INTERLEUKIN-2 AND ADOPTIVE TRANSFER OF AUTOLOGOUS LAK CELLS
    WALEWSKI, J
    PAIETTA, E
    DUTCHER, J
    WIERNIK, PH
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1989, 115 (02) : 170 - 174
  • [28] ALLOGENEIC LYMPHOKINE ACTIVATED KILLER (LAK) CELLS AND RECOMBINANT INTERLEUKIN-2 (RIL-2) REDUCE ESTABLISHED PULMONARY METASTASES
    SHILONI, E
    MULE, JJ
    SCHWARZ, S
    ROSENBERG, SA
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 362 - 362
  • [29] QUANTIFICATION OF EFFECTOR TARGET CONJUGATION INVOLVING NATURAL-KILLER (NK) OR LYMPHOKINE ACTIVATED KILLER (LAK) CELLS BY 2-COLOR FLOW-CYTOMETRY
    RADCLIFF, G
    WAITE, R
    LEFEVRE, J
    POULIK, MD
    CALLEWAERT, DM
    JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 139 (02) : 281 - 292
  • [30] SEPARATION AND ISOLATION OF RAT NATURAL-KILLER (NK) CELLS FROM T-CELLS WITH MONOCLONAL-ANTIBODIES
    WODA, BA
    MCFADDEN, ML
    WELSH, RM
    BAIN, KM
    JOURNAL OF IMMUNOLOGY, 1984, 132 (05): : 2183 - 2184
12345